nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—Melatonin—MT3—urinary bladder cancer	0.0168	0.231	CrCbGaD
Agomelatine—CYP1A2—Fluorouracil—urinary bladder cancer	0.0149	0.286	CbGbCtD
Agomelatine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0135	0.257	CbGbCtD
Agomelatine—CYP1A2—Etoposide—urinary bladder cancer	0.0125	0.238	CbGbCtD
Agomelatine—Naproxen—UGT2B7—urinary bladder cancer	0.0115	0.158	CrCbGaD
Agomelatine—CYP2C9—Cisplatin—urinary bladder cancer	0.0114	0.219	CbGbCtD
Agomelatine—Nabumetone—MPO—urinary bladder cancer	0.0109	0.151	CrCbGaD
Agomelatine—Indomethacin—UGT2B7—urinary bladder cancer	0.0093	0.128	CrCbGaD
Agomelatine—Indomethacin—CXCL8—urinary bladder cancer	0.00526	0.0725	CrCbGaD
Agomelatine—Influenza—Gemcitabine—urinary bladder cancer	0.0045	0.00644	CcSEcCtD
Agomelatine—Rash erythematous—Epirubicin—urinary bladder cancer	0.00448	0.00642	CcSEcCtD
Agomelatine—Melatonin—MPO—urinary bladder cancer	0.00434	0.06	CrCbGaD
Agomelatine—Asthenia—Mitomycin—urinary bladder cancer	0.00434	0.00621	CcSEcCtD
Agomelatine—Nasopharyngitis—Cisplatin—urinary bladder cancer	0.00434	0.00621	CcSEcCtD
Agomelatine—Hallucination—Thiotepa—urinary bladder cancer	0.00426	0.0061	CcSEcCtD
Agomelatine—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.00421	0.00602	CcSEcCtD
Agomelatine—Rash erythematous—Doxorubicin—urinary bladder cancer	0.00415	0.00594	CcSEcCtD
Agomelatine—Diarrhoea—Mitomycin—urinary bladder cancer	0.00414	0.00593	CcSEcCtD
Agomelatine—Nabumetone—PTGS2—urinary bladder cancer	0.00409	0.0565	CrCbGaD
Agomelatine—Eye disorder—Thiotepa—urinary bladder cancer	0.004	0.00573	CcSEcCtD
Agomelatine—Dizziness—Mitomycin—urinary bladder cancer	0.004	0.00573	CcSEcCtD
Agomelatine—Tinnitus—Thiotepa—urinary bladder cancer	0.00399	0.00572	CcSEcCtD
Agomelatine—Infestation NOS—Fluorouracil—urinary bladder cancer	0.00394	0.00565	CcSEcCtD
Agomelatine—Infestation—Fluorouracil—urinary bladder cancer	0.00394	0.00565	CcSEcCtD
Agomelatine—Vomiting—Mitomycin—urinary bladder cancer	0.00385	0.00551	CcSEcCtD
Agomelatine—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.00379	0.00543	CcSEcCtD
Agomelatine—Headache—Mitomycin—urinary bladder cancer	0.00379	0.00543	CcSEcCtD
Agomelatine—Mental disorder—Thiotepa—urinary bladder cancer	0.00375	0.00537	CcSEcCtD
Agomelatine—Indomethacin—PPARG—urinary bladder cancer	0.00363	0.0501	CrCbGaD
Agomelatine—Back pain—Thiotepa—urinary bladder cancer	0.0036	0.00516	CcSEcCtD
Agomelatine—Nausea—Mitomycin—urinary bladder cancer	0.00359	0.00514	CcSEcCtD
Agomelatine—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00354	0.00507	CcSEcCtD
Agomelatine—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.00354	0.00506	CcSEcCtD
Agomelatine—Vision blurred—Thiotepa—urinary bladder cancer	0.00351	0.00503	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Epirubicin—urinary bladder cancer	0.00343	0.00492	CcSEcCtD
Agomelatine—Infestation NOS—Etoposide—urinary bladder cancer	0.00343	0.00491	CcSEcCtD
Agomelatine—Infestation—Etoposide—urinary bladder cancer	0.00343	0.00491	CcSEcCtD
Agomelatine—Agitation—Thiotepa—urinary bladder cancer	0.00342	0.0049	CcSEcCtD
Agomelatine—Abnormal dreams—Epirubicin—urinary bladder cancer	0.00339	0.00486	CcSEcCtD
Agomelatine—Jaundice—Etoposide—urinary bladder cancer	0.00334	0.00478	CcSEcCtD
Agomelatine—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.0033	0.00472	CcSEcCtD
Agomelatine—Melatonin—ESR1—urinary bladder cancer	0.00326	0.045	CrCbGaD
Agomelatine—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.00324	0.00464	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Doxorubicin—urinary bladder cancer	0.00318	0.00455	CcSEcCtD
Agomelatine—Anxiety—Thiotepa—urinary bladder cancer	0.00316	0.00453	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.00315	0.00451	CcSEcCtD
Agomelatine—Abnormal dreams—Doxorubicin—urinary bladder cancer	0.00314	0.00449	CcSEcCtD
Agomelatine—Eye disorder—Cisplatin—urinary bladder cancer	0.00314	0.00449	CcSEcCtD
Agomelatine—Tinnitus—Cisplatin—urinary bladder cancer	0.00313	0.00448	CcSEcCtD
Agomelatine—Back pain—Gemcitabine—urinary bladder cancer	0.00303	0.00434	CcSEcCtD
Agomelatine—Infection—Thiotepa—urinary bladder cancer	0.00302	0.00433	CcSEcCtD
Agomelatine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00298	0.00427	CcSEcCtD
Agomelatine—Hepatic failure—Methotrexate—urinary bladder cancer	0.00296	0.00424	CcSEcCtD
Agomelatine—Skin disorder—Thiotepa—urinary bladder cancer	0.00295	0.00423	CcSEcCtD
Agomelatine—Vision blurred—Fluorouracil—urinary bladder cancer	0.0029	0.00416	CcSEcCtD
Agomelatine—Eye disorder—Etoposide—urinary bladder cancer	0.00287	0.00412	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.00286	0.0041	CcSEcCtD
Agomelatine—Eczema—Epirubicin—urinary bladder cancer	0.00277	0.00397	CcSEcCtD
Agomelatine—Hepatic failure—Epirubicin—urinary bladder cancer	0.00277	0.00397	CcSEcCtD
Agomelatine—Vision blurred—Cisplatin—urinary bladder cancer	0.00275	0.00394	CcSEcCtD
Agomelatine—Tremor—Cisplatin—urinary bladder cancer	0.00274	0.00392	CcSEcCtD
Agomelatine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00273	0.00391	CcSEcCtD
Agomelatine—Somnolence—Thiotepa—urinary bladder cancer	0.0027	0.00387	CcSEcCtD
Agomelatine—Dyspepsia—Thiotepa—urinary bladder cancer	0.00268	0.00383	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.00265	0.0038	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.00265	0.0038	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00263	0.00376	CcSEcCtD
Agomelatine—Fatigue—Thiotepa—urinary bladder cancer	0.00262	0.00375	CcSEcCtD
Agomelatine—Constipation—Thiotepa—urinary bladder cancer	0.0026	0.00372	CcSEcCtD
Agomelatine—Back pain—Etoposide—urinary bladder cancer	0.00259	0.00371	CcSEcCtD
Agomelatine—Eczema—Doxorubicin—urinary bladder cancer	0.00257	0.00367	CcSEcCtD
Agomelatine—Hepatic failure—Doxorubicin—urinary bladder cancer	0.00257	0.00367	CcSEcCtD
Agomelatine—Infection—Gemcitabine—urinary bladder cancer	0.00254	0.00364	CcSEcCtD
Agomelatine—Irritability—Methotrexate—urinary bladder cancer	0.00254	0.00364	CcSEcCtD
Agomelatine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00251	0.00359	CcSEcCtD
Agomelatine—Infection—Fluorouracil—urinary bladder cancer	0.0025	0.00358	CcSEcCtD
Agomelatine—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.00249	0.00356	CcSEcCtD
Agomelatine—Skin disorder—Gemcitabine—urinary bladder cancer	0.00249	0.00356	CcSEcCtD
Agomelatine—Anxiety—Cisplatin—urinary bladder cancer	0.00248	0.00355	CcSEcCtD
Agomelatine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.00247	0.00354	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.00247	0.00354	CcSEcCtD
Agomelatine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00247	0.00353	CcSEcCtD
Agomelatine—Migraine—Epirubicin—urinary bladder cancer	0.00245	0.00351	CcSEcCtD
Agomelatine—Urticaria—Thiotepa—urinary bladder cancer	0.00242	0.00346	CcSEcCtD
Agomelatine—Face oedema—Epirubicin—urinary bladder cancer	0.00241	0.00344	CcSEcCtD
Agomelatine—Vertigo—Etoposide—urinary bladder cancer	0.0024	0.00344	CcSEcCtD
Agomelatine—Abdominal pain—Thiotepa—urinary bladder cancer	0.0024	0.00344	CcSEcCtD
Agomelatine—Infection—Cisplatin—urinary bladder cancer	0.00237	0.00339	CcSEcCtD
Agomelatine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00234	0.00335	CcSEcCtD
Agomelatine—Skin disorder—Cisplatin—urinary bladder cancer	0.00232	0.00332	CcSEcCtD
Agomelatine—Insomnia—Gemcitabine—urinary bladder cancer	0.00231	0.00331	CcSEcCtD
Agomelatine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.00231	0.0033	CcSEcCtD
Agomelatine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.0023	0.00329	CcSEcCtD
Agomelatine—Insomnia—Fluorouracil—urinary bladder cancer	0.00228	0.00326	CcSEcCtD
Agomelatine—Somnolence—Gemcitabine—urinary bladder cancer	0.00227	0.00326	CcSEcCtD
Agomelatine—Migraine—Doxorubicin—urinary bladder cancer	0.00227	0.00325	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00226	0.00324	CcSEcCtD
Agomelatine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00226	0.00323	CcSEcCtD
Agomelatine—Somnolence—Fluorouracil—urinary bladder cancer	0.00224	0.0032	CcSEcCtD
Agomelatine—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.00223	0.00319	CcSEcCtD
Agomelatine—Face oedema—Doxorubicin—urinary bladder cancer	0.00223	0.00319	CcSEcCtD
Agomelatine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.00221	0.00317	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00221	0.00316	CcSEcCtD
Agomelatine—Fatigue—Gemcitabine—urinary bladder cancer	0.00221	0.00316	CcSEcCtD
Agomelatine—Constipation—Gemcitabine—urinary bladder cancer	0.00219	0.00313	CcSEcCtD
Agomelatine—Asthenia—Thiotepa—urinary bladder cancer	0.00218	0.00312	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00217	0.00311	CcSEcCtD
Agomelatine—Infection—Etoposide—urinary bladder cancer	0.00217	0.00311	CcSEcCtD
Agomelatine—Influenza—Epirubicin—urinary bladder cancer	0.00215	0.00308	CcSEcCtD
Agomelatine—Pruritus—Thiotepa—urinary bladder cancer	0.00215	0.00308	CcSEcCtD
Agomelatine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00214	0.00307	CcSEcCtD
Agomelatine—Skin disorder—Etoposide—urinary bladder cancer	0.00212	0.00304	CcSEcCtD
Agomelatine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.00211	0.00302	CcSEcCtD
Agomelatine—Diarrhoea—Thiotepa—urinary bladder cancer	0.00208	0.00298	CcSEcCtD
Agomelatine—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.00206	0.00295	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.00206	0.00295	CcSEcCtD
Agomelatine—Infestation—Methotrexate—urinary bladder cancer	0.00205	0.00294	CcSEcCtD
Agomelatine—Infestation NOS—Methotrexate—urinary bladder cancer	0.00205	0.00294	CcSEcCtD
Agomelatine—Depression—Methotrexate—urinary bladder cancer	0.00205	0.00293	CcSEcCtD
Agomelatine—Dizziness—Thiotepa—urinary bladder cancer	0.00201	0.00288	CcSEcCtD
Agomelatine—Urticaria—Fluorouracil—urinary bladder cancer	0.002	0.00286	CcSEcCtD
Agomelatine—Influenza—Doxorubicin—urinary bladder cancer	0.00199	0.00285	CcSEcCtD
Agomelatine—Paraesthesia—Etoposide—urinary bladder cancer	0.00196	0.00281	CcSEcCtD
Agomelatine—Weight increased—Epirubicin—urinary bladder cancer	0.00196	0.00281	CcSEcCtD
Agomelatine—Weight decreased—Epirubicin—urinary bladder cancer	0.00195	0.00279	CcSEcCtD
Agomelatine—Somnolence—Etoposide—urinary bladder cancer	0.00194	0.00278	CcSEcCtD
Agomelatine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00194	0.00278	CcSEcCtD
Agomelatine—Vomiting—Thiotepa—urinary bladder cancer	0.00193	0.00277	CcSEcCtD
Agomelatine—Infestation NOS—Epirubicin—urinary bladder cancer	0.00192	0.00275	CcSEcCtD
Agomelatine—Infestation—Epirubicin—urinary bladder cancer	0.00192	0.00275	CcSEcCtD
Agomelatine—Headache—Thiotepa—urinary bladder cancer	0.00191	0.00273	CcSEcCtD
Agomelatine—Naproxen—PTGS2—urinary bladder cancer	0.00189	0.0261	CrCbGaD
Agomelatine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00189	0.0027	CcSEcCtD
Agomelatine—Fatigue—Etoposide—urinary bladder cancer	0.00188	0.0027	CcSEcCtD
Agomelatine—Jaundice—Epirubicin—urinary bladder cancer	0.00187	0.00268	CcSEcCtD
Agomelatine—Constipation—Etoposide—urinary bladder cancer	0.00187	0.00268	CcSEcCtD
Agomelatine—Hepatitis—Methotrexate—urinary bladder cancer	0.00184	0.00264	CcSEcCtD
Agomelatine—Asthenia—Gemcitabine—urinary bladder cancer	0.00184	0.00263	CcSEcCtD
Agomelatine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00182	0.0026	CcSEcCtD
Agomelatine—Weight increased—Doxorubicin—urinary bladder cancer	0.00181	0.0026	CcSEcCtD
Agomelatine—Pruritus—Gemcitabine—urinary bladder cancer	0.00181	0.00259	CcSEcCtD
Agomelatine—Nausea—Thiotepa—urinary bladder cancer	0.00181	0.00259	CcSEcCtD
Agomelatine—Weight decreased—Doxorubicin—urinary bladder cancer	0.0018	0.00258	CcSEcCtD
Agomelatine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00179	0.00256	CcSEcCtD
Agomelatine—Pruritus—Fluorouracil—urinary bladder cancer	0.00178	0.00255	CcSEcCtD
Agomelatine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00178	0.00254	CcSEcCtD
Agomelatine—Infestation—Doxorubicin—urinary bladder cancer	0.00178	0.00254	CcSEcCtD
Agomelatine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.00175	0.00251	CcSEcCtD
Agomelatine—Urticaria—Etoposide—urinary bladder cancer	0.00174	0.00249	CcSEcCtD
Agomelatine—Jaundice—Doxorubicin—urinary bladder cancer	0.00173	0.00248	CcSEcCtD
Agomelatine—Abdominal pain—Etoposide—urinary bladder cancer	0.00173	0.00247	CcSEcCtD
Agomelatine—Hepatitis—Epirubicin—urinary bladder cancer	0.00172	0.00247	CcSEcCtD
Agomelatine—Eye disorder—Methotrexate—urinary bladder cancer	0.00172	0.00246	CcSEcCtD
Agomelatine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.00172	0.00246	CcSEcCtD
Agomelatine—Tinnitus—Methotrexate—urinary bladder cancer	0.00172	0.00246	CcSEcCtD
Agomelatine—Asthenia—Cisplatin—urinary bladder cancer	0.00171	0.00245	CcSEcCtD
Agomelatine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00169	0.00243	CcSEcCtD
Agomelatine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00168	0.00241	CcSEcCtD
Agomelatine—Dizziness—Fluorouracil—urinary bladder cancer	0.00166	0.00238	CcSEcCtD
Agomelatine—Diarrhoea—Cisplatin—urinary bladder cancer	0.00163	0.00234	CcSEcCtD
Agomelatine—Vomiting—Gemcitabine—urinary bladder cancer	0.00163	0.00233	CcSEcCtD
Agomelatine—Mental disorder—Methotrexate—urinary bladder cancer	0.00161	0.00231	CcSEcCtD
Agomelatine—Eye disorder—Epirubicin—urinary bladder cancer	0.00161	0.00231	CcSEcCtD
Agomelatine—Tinnitus—Epirubicin—urinary bladder cancer	0.00161	0.0023	CcSEcCtD
Agomelatine—Headache—Gemcitabine—urinary bladder cancer	0.0016	0.0023	CcSEcCtD
Agomelatine—Vomiting—Fluorouracil—urinary bladder cancer	0.0016	0.00229	CcSEcCtD
Agomelatine—Hepatitis—Doxorubicin—urinary bladder cancer	0.00159	0.00228	CcSEcCtD
Agomelatine—Headache—Fluorouracil—urinary bladder cancer	0.00158	0.00226	CcSEcCtD
Agomelatine—Asthenia—Etoposide—urinary bladder cancer	0.00157	0.00224	CcSEcCtD
Agomelatine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.00157	0.00224	CcSEcCtD
Agomelatine—Back pain—Methotrexate—urinary bladder cancer	0.00155	0.00222	CcSEcCtD
Agomelatine—Pruritus—Etoposide—urinary bladder cancer	0.00155	0.00221	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—urinary bladder cancer	0.00153	0.0212	CrCbGaD
Agomelatine—Nausea—Gemcitabine—urinary bladder cancer	0.00152	0.00218	CcSEcCtD
Agomelatine—Vomiting—Cisplatin—urinary bladder cancer	0.00152	0.00217	CcSEcCtD
Agomelatine—Vision blurred—Methotrexate—urinary bladder cancer	0.00151	0.00216	CcSEcCtD
Agomelatine—Mental disorder—Epirubicin—urinary bladder cancer	0.00151	0.00216	CcSEcCtD
Agomelatine—Diarrhoea—Etoposide—urinary bladder cancer	0.00149	0.00214	CcSEcCtD
Agomelatine—Nausea—Fluorouracil—urinary bladder cancer	0.00149	0.00214	CcSEcCtD
Agomelatine—Eye disorder—Doxorubicin—urinary bladder cancer	0.00149	0.00213	CcSEcCtD
Agomelatine—Tinnitus—Doxorubicin—urinary bladder cancer	0.00149	0.00213	CcSEcCtD
Agomelatine—Back pain—Epirubicin—urinary bladder cancer	0.00145	0.00208	CcSEcCtD
Agomelatine—Dizziness—Etoposide—urinary bladder cancer	0.00144	0.00207	CcSEcCtD
Agomelatine—Vertigo—Methotrexate—urinary bladder cancer	0.00144	0.00206	CcSEcCtD
Agomelatine—Nausea—Cisplatin—urinary bladder cancer	0.00142	0.00203	CcSEcCtD
Agomelatine—Vision blurred—Epirubicin—urinary bladder cancer	0.00141	0.00203	CcSEcCtD
Agomelatine—Mental disorder—Doxorubicin—urinary bladder cancer	0.0014	0.002	CcSEcCtD
Agomelatine—Vomiting—Etoposide—urinary bladder cancer	0.00139	0.00199	CcSEcCtD
Agomelatine—Agitation—Epirubicin—urinary bladder cancer	0.00138	0.00197	CcSEcCtD
Agomelatine—Headache—Etoposide—urinary bladder cancer	0.00137	0.00196	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00136	0.00194	CcSEcCtD
Agomelatine—Vertigo—Epirubicin—urinary bladder cancer	0.00135	0.00193	CcSEcCtD
Agomelatine—Back pain—Doxorubicin—urinary bladder cancer	0.00134	0.00192	CcSEcCtD
Agomelatine—Vision blurred—Doxorubicin—urinary bladder cancer	0.00131	0.00187	CcSEcCtD
Agomelatine—Infection—Methotrexate—urinary bladder cancer	0.0013	0.00186	CcSEcCtD
Agomelatine—Nausea—Etoposide—urinary bladder cancer	0.0013	0.00186	CcSEcCtD
Agomelatine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.00128	0.00184	CcSEcCtD
Agomelatine—Agitation—Doxorubicin—urinary bladder cancer	0.00128	0.00183	CcSEcCtD
Agomelatine—Anxiety—Epirubicin—urinary bladder cancer	0.00127	0.00182	CcSEcCtD
Agomelatine—Skin disorder—Methotrexate—urinary bladder cancer	0.00127	0.00182	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00127	0.00182	CcSEcCtD
Agomelatine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00127	0.00181	CcSEcCtD
Agomelatine—Dry mouth—Epirubicin—urinary bladder cancer	0.00125	0.00179	CcSEcCtD
Agomelatine—Vertigo—Doxorubicin—urinary bladder cancer	0.00125	0.00179	CcSEcCtD
Agomelatine—Infection—Epirubicin—urinary bladder cancer	0.00122	0.00174	CcSEcCtD
Agomelatine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.0012	0.00172	CcSEcCtD
Agomelatine—Skin disorder—Epirubicin—urinary bladder cancer	0.00119	0.0017	CcSEcCtD
Agomelatine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.00118	0.0017	CcSEcCtD
Agomelatine—Insomnia—Methotrexate—urinary bladder cancer	0.00118	0.00169	CcSEcCtD
Agomelatine—Anxiety—Doxorubicin—urinary bladder cancer	0.00118	0.00169	CcSEcCtD
Agomelatine—Paraesthesia—Methotrexate—urinary bladder cancer	0.00118	0.00168	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.00117	0.00168	CcSEcCtD
Agomelatine—Somnolence—Methotrexate—urinary bladder cancer	0.00116	0.00167	CcSEcCtD
Agomelatine—Dry mouth—Doxorubicin—urinary bladder cancer	0.00116	0.00166	CcSEcCtD
Agomelatine—Dyspepsia—Methotrexate—urinary bladder cancer	0.00115	0.00165	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.00113	0.00162	CcSEcCtD
Agomelatine—Fatigue—Methotrexate—urinary bladder cancer	0.00113	0.00162	CcSEcCtD
Agomelatine—Infection—Doxorubicin—urinary bladder cancer	0.00113	0.00161	CcSEcCtD
Agomelatine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00111	0.00159	CcSEcCtD
Agomelatine—Insomnia—Epirubicin—urinary bladder cancer	0.00111	0.00159	CcSEcCtD
Agomelatine—Skin disorder—Doxorubicin—urinary bladder cancer	0.0011	0.00158	CcSEcCtD
Agomelatine—Paraesthesia—Epirubicin—urinary bladder cancer	0.0011	0.00157	CcSEcCtD
Agomelatine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.0011	0.00157	CcSEcCtD
Agomelatine—Somnolence—Epirubicin—urinary bladder cancer	0.00109	0.00156	CcSEcCtD
Agomelatine—Dyspepsia—Epirubicin—urinary bladder cancer	0.00108	0.00154	CcSEcCtD
Agomelatine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.00107	0.00153	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00106	0.00151	CcSEcCtD
Agomelatine—Fatigue—Epirubicin—urinary bladder cancer	0.00106	0.00151	CcSEcCtD
Agomelatine—Constipation—Epirubicin—urinary bladder cancer	0.00105	0.0015	CcSEcCtD
Agomelatine—Urticaria—Methotrexate—urinary bladder cancer	0.00104	0.00149	CcSEcCtD
Agomelatine—Abdominal pain—Methotrexate—urinary bladder cancer	0.00103	0.00148	CcSEcCtD
Agomelatine—Insomnia—Doxorubicin—urinary bladder cancer	0.00102	0.00147	CcSEcCtD
Agomelatine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00102	0.00146	CcSEcCtD
Agomelatine—Somnolence—Doxorubicin—urinary bladder cancer	0.00101	0.00144	CcSEcCtD
Agomelatine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.001	0.00143	CcSEcCtD
Agomelatine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000997	0.00143	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000978	0.0014	CcSEcCtD
Agomelatine—Fatigue—Doxorubicin—urinary bladder cancer	0.000977	0.0014	CcSEcCtD
Agomelatine—Urticaria—Epirubicin—urinary bladder cancer	0.000973	0.00139	CcSEcCtD
Agomelatine—Constipation—Doxorubicin—urinary bladder cancer	0.000969	0.00139	CcSEcCtD
Agomelatine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000968	0.00139	CcSEcCtD
Agomelatine—Asthenia—Methotrexate—urinary bladder cancer	0.000939	0.00134	CcSEcCtD
Agomelatine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000927	0.00133	CcSEcCtD
Agomelatine—Pruritus—Methotrexate—urinary bladder cancer	0.000926	0.00133	CcSEcCtD
Agomelatine—Urticaria—Doxorubicin—urinary bladder cancer	0.0009	0.00129	CcSEcCtD
Agomelatine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000896	0.00128	CcSEcCtD
Agomelatine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000895	0.00128	CcSEcCtD
Agomelatine—Asthenia—Epirubicin—urinary bladder cancer	0.000879	0.00126	CcSEcCtD
Agomelatine—Pruritus—Epirubicin—urinary bladder cancer	0.000866	0.00124	CcSEcCtD
Agomelatine—Dizziness—Methotrexate—urinary bladder cancer	0.000865	0.00124	CcSEcCtD
Agomelatine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000838	0.0012	CcSEcCtD
Agomelatine—Vomiting—Methotrexate—urinary bladder cancer	0.000832	0.00119	CcSEcCtD
Agomelatine—Headache—Methotrexate—urinary bladder cancer	0.00082	0.00117	CcSEcCtD
Agomelatine—Asthenia—Doxorubicin—urinary bladder cancer	0.000813	0.00116	CcSEcCtD
Agomelatine—Dizziness—Epirubicin—urinary bladder cancer	0.00081	0.00116	CcSEcCtD
Agomelatine—Pruritus—Doxorubicin—urinary bladder cancer	0.000802	0.00115	CcSEcCtD
Agomelatine—Vomiting—Epirubicin—urinary bladder cancer	0.000779	0.00111	CcSEcCtD
Agomelatine—Nausea—Methotrexate—urinary bladder cancer	0.000777	0.00111	CcSEcCtD
Agomelatine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000775	0.00111	CcSEcCtD
Agomelatine—Headache—Epirubicin—urinary bladder cancer	0.000767	0.0011	CcSEcCtD
Agomelatine—Dizziness—Doxorubicin—urinary bladder cancer	0.000749	0.00107	CcSEcCtD
Agomelatine—Nausea—Epirubicin—urinary bladder cancer	0.000727	0.00104	CcSEcCtD
Agomelatine—Vomiting—Doxorubicin—urinary bladder cancer	0.00072	0.00103	CcSEcCtD
Agomelatine—Headache—Doxorubicin—urinary bladder cancer	0.00071	0.00102	CcSEcCtD
Agomelatine—Nausea—Doxorubicin—urinary bladder cancer	0.000673	0.000964	CcSEcCtD
Agomelatine—MTNR1B—Signaling Pathways—RBX1—urinary bladder cancer	0.000451	0.00255	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—RBX1—urinary bladder cancer	0.000451	0.00255	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000442	0.0025	CbGpPWpGaD
Agomelatine—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000434	0.00246	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000429	0.00243	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TSC1—urinary bladder cancer	0.000424	0.0024	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TSC1—urinary bladder cancer	0.000424	0.0024	CbGpPWpGaD
Agomelatine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000414	0.00234	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—JAG1—urinary bladder cancer	0.000404	0.00228	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—JAG1—urinary bladder cancer	0.000404	0.00228	CbGpPWpGaD
Agomelatine—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000399	0.00226	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000378	0.00214	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000378	0.00214	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000367	0.00207	CbGpPWpGaD
Agomelatine—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000354	0.002	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.00035	0.00198	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000341	0.00193	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000341	0.00193	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.00033	0.00187	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—S100B—urinary bladder cancer	0.000327	0.00185	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—S100B—urinary bladder cancer	0.000327	0.00185	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000319	0.00181	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000314	0.00178	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000314	0.00178	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—RHOA—urinary bladder cancer	0.00031	0.00175	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—RHOA—urinary bladder cancer	0.00031	0.00175	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000306	0.00173	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000306	0.00173	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.0003	0.00169	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	0.0003	0.00169	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000297	0.00168	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NCOR1—urinary bladder cancer	0.000294	0.00166	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NCOR1—urinary bladder cancer	0.000294	0.00166	CbGpPWpGaD
Agomelatine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000293	0.00166	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—IL2—urinary bladder cancer	0.000286	0.00162	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—IL2—urinary bladder cancer	0.000286	0.00162	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000274	0.00155	CbGpPWpGaD
Agomelatine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000273	0.00154	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000273	0.00154	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000272	0.00154	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	0.000272	0.00154	CbGpPWpGaD
Agomelatine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00027	0.00152	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000268	0.00152	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000268	0.00152	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—IL2—urinary bladder cancer	0.00026	0.00147	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—IL2—urinary bladder cancer	0.00026	0.00147	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TERT—urinary bladder cancer	0.000259	0.00146	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TERT—urinary bladder cancer	0.000259	0.00146	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000255	0.00144	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000255	0.00144	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000254	0.00144	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HDAC4—urinary bladder cancer	0.000254	0.00143	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000253	0.00143	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000251	0.00142	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—FGFR3—urinary bladder cancer	0.000238	0.00134	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—FGFR3—urinary bladder cancer	0.000238	0.00134	CbGpPWpGaD
Agomelatine—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000234	0.00132	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—ESR1—urinary bladder cancer	0.000231	0.00131	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—ESR1—urinary bladder cancer	0.000231	0.00131	CbGpPWpGaD
Agomelatine—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00023	0.0013	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000225	0.00127	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000222	0.00125	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000215	0.00122	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GLI1—urinary bladder cancer	0.000212	0.0012	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.00021	0.00118	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HDAC4—urinary bladder cancer	0.000205	0.00116	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CREBBP—urinary bladder cancer	0.000202	0.00114	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CREBBP—urinary bladder cancer	0.000202	0.00114	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IGF1—urinary bladder cancer	0.0002	0.00113	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IGF1—urinary bladder cancer	0.0002	0.00113	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—EGFR—urinary bladder cancer	0.000199	0.00112	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—EGFR—urinary bladder cancer	0.000199	0.00112	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—KRAS—urinary bladder cancer	0.000188	0.00106	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—KRAS—urinary bladder cancer	0.000188	0.00106	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—RHOA—urinary bladder cancer	0.000183	0.00104	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—RHOA—urinary bladder cancer	0.000183	0.00104	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000182	0.00103	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000181	0.00103	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000179	0.00101	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000178	0.00101	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000173	0.000976	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000173	0.000976	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GLI1—urinary bladder cancer	0.000171	0.000969	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000171	0.000968	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.00017	0.00096	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—ERBB2—urinary bladder cancer	0.000169	0.000958	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—ERBB2—urinary bladder cancer	0.000169	0.000958	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000169	0.000956	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CXCL8—urinary bladder cancer	0.000161	0.000909	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CXCL8—urinary bladder cancer	0.000161	0.000909	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—HRAS—urinary bladder cancer	0.00016	0.000903	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HRAS—urinary bladder cancer	0.00016	0.000903	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.000158	0.000893	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000156	0.00088	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL2—urinary bladder cancer	0.000154	0.000868	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL2—urinary bladder cancer	0.000154	0.000868	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CCND1—urinary bladder cancer	0.00015	0.000847	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CCND1—urinary bladder cancer	0.00015	0.000847	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	0.000148	0.000834	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NAT1—urinary bladder cancer	0.000148	0.000834	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RBX1—urinary bladder cancer	0.000146	0.000823	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MMP9—urinary bladder cancer	0.000145	0.000822	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MMP9—urinary bladder cancer	0.000145	0.000822	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000145	0.00082	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000145	0.000819	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—CDKN1A—urinary bladder cancer	0.000145	0.000819	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTEN—urinary bladder cancer	0.000145	0.000817	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTEN—urinary bladder cancer	0.000145	0.000817	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000144	0.000812	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	0.000142	0.000804	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000138	0.000781	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—EP300—urinary bladder cancer	0.000138	0.000779	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—EP300—urinary bladder cancer	0.000138	0.000779	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TSC1—urinary bladder cancer	0.000137	0.000774	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	0.000135	0.000763	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	0.000134	0.000759	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SRC—urinary bladder cancer	0.000134	0.000758	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SRC—urinary bladder cancer	0.000134	0.000758	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	0.000131	0.00074	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—JAG1—urinary bladder cancer	0.00013	0.000737	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	0.000122	0.000687	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MYC—urinary bladder cancer	0.00012	0.000679	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MYC—urinary bladder cancer	0.00012	0.000679	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—EGFR—urinary bladder cancer	0.000117	0.000664	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—EGFR—urinary bladder cancer	0.000117	0.000664	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RBX1—urinary bladder cancer	0.000117	0.000664	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	0.000115	0.000649	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	0.000112	0.000632	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KRAS—urinary bladder cancer	0.000111	0.000627	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KRAS—urinary bladder cancer	0.000111	0.000627	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TSC1—urinary bladder cancer	0.00011	0.000624	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—RHOA—urinary bladder cancer	0.00011	0.000623	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—S100B—urinary bladder cancer	0.000106	0.000597	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—JAG1—urinary bladder cancer	0.000105	0.000594	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000105	0.000593	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	0.000105	0.000591	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.0001	0.000568	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—RHOA—urinary bladder cancer	0.0001	0.000566	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—urinary bladder cancer	9.86e-05	0.000558	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—urinary bladder cancer	9.86e-05	0.000558	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—CXCL8—urinary bladder cancer	9.67e-05	0.000547	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NCOR1—urinary bladder cancer	9.49e-05	0.000536	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	9.46e-05	0.000535	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—urinary bladder cancer	9.43e-05	0.000533	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—urinary bladder cancer	9.43e-05	0.000533	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—IL2—urinary bladder cancer	9.24e-05	0.000523	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.97e-05	0.000507	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	8.94e-05	0.000505	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—RHOA—urinary bladder cancer	8.89e-05	0.000502	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—CXCL8—urinary bladder cancer	8.78e-05	0.000497	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	8.59e-05	0.000485	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—S100B—urinary bladder cancer	8.52e-05	0.000481	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL2—urinary bladder cancer	8.39e-05	0.000475	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—urinary bladder cancer	8.36e-05	0.000473	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	8.17e-05	0.000462	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	8.09e-05	0.000457	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—RHOA—urinary bladder cancer	8.07e-05	0.000456	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—CXCL8—urinary bladder cancer	7.8e-05	0.000441	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FGFR3—urinary bladder cancer	7.68e-05	0.000434	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NCOR1—urinary bladder cancer	7.66e-05	0.000433	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	7.56e-05	0.000428	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	7.56e-05	0.000428	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	7.52e-05	0.000425	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—IL2—urinary bladder cancer	7.46e-05	0.000422	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ESR1—urinary bladder cancer	7.45e-05	0.000421	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	7.34e-05	0.000415	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	7.22e-05	0.000408	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—CXCL8—urinary bladder cancer	7.09e-05	0.000401	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	6.98e-05	0.000395	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL2—urinary bladder cancer	6.77e-05	0.000383	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—urinary bladder cancer	6.75e-05	0.000381	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CREBBP—urinary bladder cancer	6.53e-05	0.000369	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	6.46e-05	0.000365	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	6.46e-05	0.000365	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IGF1—urinary bladder cancer	6.45e-05	0.000365	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	6.43e-05	0.000363	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—EGFR—urinary bladder cancer	6.42e-05	0.000363	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	6.27e-05	0.000354	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FGFR3—urinary bladder cancer	6.19e-05	0.00035	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	6.17e-05	0.000349	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	6.1e-05	0.000345	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—urinary bladder cancer	6.07e-05	0.000343	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ESR1—urinary bladder cancer	6.01e-05	0.00034	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.92e-05	0.000334	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RHOA—urinary bladder cancer	5.91e-05	0.000334	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—ERBB2—urinary bladder cancer	5.47e-05	0.000309	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CREBBP—urinary bladder cancer	5.27e-05	0.000298	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	5.21e-05	0.000295	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IGF1—urinary bladder cancer	5.21e-05	0.000294	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CXCL8—urinary bladder cancer	5.19e-05	0.000293	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—EGFR—urinary bladder cancer	5.18e-05	0.000293	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	5.16e-05	0.000292	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—urinary bladder cancer	5.16e-05	0.000291	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	5.09e-05	0.000287	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	5.06e-05	0.000286	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL2—urinary bladder cancer	4.96e-05	0.00028	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.92e-05	0.000278	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—urinary bladder cancer	4.89e-05	0.000277	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CCND1—urinary bladder cancer	4.83e-05	0.000273	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RHOA—urinary bladder cancer	4.77e-05	0.00027	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	4.73e-05	0.000267	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MMP9—urinary bladder cancer	4.69e-05	0.000265	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—CDKN1A—urinary bladder cancer	4.68e-05	0.000264	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	4.67e-05	0.000264	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	4.67e-05	0.000264	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTEN—urinary bladder cancer	4.67e-05	0.000264	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	4.48e-05	0.000253	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EP300—urinary bladder cancer	4.45e-05	0.000252	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—ERBB2—urinary bladder cancer	4.41e-05	0.00025	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.41e-05	0.000249	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	4.39e-05	0.000248	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	4.35e-05	0.000246	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	4.33e-05	0.000245	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	4.2e-05	0.000238	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	4.19e-05	0.000237	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	4.16e-05	0.000235	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	4.13e-05	0.000233	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	4.04e-05	0.000228	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	4e-05	0.000226	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.99e-05	0.000226	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.99e-05	0.000226	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	3.9e-05	0.00022	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	3.88e-05	0.000219	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.82e-05	0.000216	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	3.79e-05	0.000214	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	3.79e-05	0.000214	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	3.77e-05	0.000213	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	3.76e-05	0.000213	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.75e-05	0.000212	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	3.59e-05	0.000203	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	3.58e-05	0.000203	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	3.53e-05	0.000199	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	3.49e-05	0.000197	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	3.35e-05	0.000189	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	3.22e-05	0.000182	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	3.18e-05	0.00018	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	3.13e-05	0.000177	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	3.06e-05	0.000173	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	3.05e-05	0.000172	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	2.89e-05	0.000163	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.86e-05	0.000162	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.75e-05	0.000155	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	2.63e-05	0.000149	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	2.57e-05	0.000145	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	2.46e-05	0.000139	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.3e-05	0.00013	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	2.25e-05	0.000127	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.19e-05	0.000124	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.96e-05	0.000111	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.87e-05	0.000106	CbGpPWpGaD
